Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more

Conditions: Breast Cancer
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study, physiologic testing, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, psychosocial assessment and care; Drug · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Dry Eye Disease
Interventions: OTX-CSI, Placebo Vehicle; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more

Conditions: Peanut Allergy, Multi-food Allergy
Interventions: Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 55 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more

Conditions: Healthy
Interventions: PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: Influenza Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more

Conditions: Healthy Volunteer
Interventions: Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: PF-07817883, Placebo, Midazolam, Moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma, Gastric Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IV Ampulla of Vater Cancer, Stage IV Gallbladder Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer
Interventions: Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Leucovorin Calcium, Irinotecan Hydrochloride, Fluorouracil, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Substance-Related Disorders
Interventions: naltrexone for extended release injectable suspension; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pain
Interventions: Suzetrigine; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Peanut Allergy
Interventions: Whole peanut extract, Placebo formulation; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride, Leucovorin, Leucovorin Calcium, Liposomal Irinotecan, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 70 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 760
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more

Conditions: Pharmacokinetics, Drug Interactions
Interventions: Dasatinib ASD, Omeprazole 40 MG; Drug
Lead sponsor: Xspray Pharma AB; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Hypercholesterolemia
Interventions: Atorvastatin suspension, Lipitor; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
Interventions: RGX-314; Genetic
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • Sun City, Arizona • San Diego, California + 10 more

Conditions: Cystic Fibrosis, Mucociliary Clearance Defect
Interventions: Baseline (Huff-Cough alone), Oscillatory Positive Expiatory Pressure Device, Whole-Body Vibration Platform, High Frequency Chest Wall Oscillatory Vest; Other · Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet; Drug
Lead sponsor: Excalibur Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19
Interventions: PF-06650833, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Palbociclib Formulation Reference, Palbociclib Formulation Test; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Malaria, Malaria, Cerebral
Interventions: Intravenous Artesunate, Placebo; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 0 Days to 100 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more

Conditions: Cystic Fibrosis
Interventions: VX-828; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

Pre-Release VIVITROL for Opioid Dependent Inmates

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Bioavailability Study for New Atorvastatin Formulation

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

Study of the Safety of Intravenous Artesunate

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation